In this 2-year follow-up study, we found a significant positive association between the change in the extent of M1 and change in ODI. We also found a positive association between the change in the ...
Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353 has the potential to ...
Objective: The aim of this study was to assess the clinical effect of antibiotic treatment in a cohort of patients with low-back pain (LBP) and Modic changes Type 1 (bone oedema) following a lumbar ...
London, UK, 3 February 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results